Study to Probe & Assess Registry-Claims Linkage for Juvenile Idiopathic Arthritis (SPARCLe-JIA)

About This Grant

Juvenile idiopathic arthritis (JIA) is a chronic illness involving complex treatment plans with varying benefits and risks. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry collects extensive clinical and patient-/parent-reported data on over 12,000 North American children with JIA. However, the Registry lacks data on healthcare utilization, medication dispensing, and patients who do not consent, limiting its utility. Claims databases are large population-based datasets that permit study of large populations, rare diseases, and wide range of outcomes. However, claims data lack potentially critical clinical measures such as disease activity and patient-/parent-reported outcomes. To address these gaps and facilitate future observational and interventional clinical studies, we will perform the Study to Probe & Appraise Registry-Claims Linkage for Juvenile Idiopathic Arthritis (SPARCLe-JIA). This study aims to assess CARRA Registry data linked with the Komodo national claims database (>50,000 children and youth diagnosed with JIA). This linked dataset will allow for a comprehensive evaluation of the Registry's data coverage, consistency, and utility for conducting rigorous and broadly applicable research on JIA. The specific aims are: 1) to compare the characteristics of linked versus unlinked patients with JIA within the Registry and claims data; 2) to compare rates of uveitis and hospitalizations across datasets and evaluate whether use of linked data results in greater validity for an applied question on tumor necrosis factor inhibitors and hospitalized infection; and 3) to investigate how delays in biologic drug dispensing affect subsequent disease activity—a proof-of-concept study that can only be done using linked Registry and claims data. SPARCLe-JIA employs advanced analytical approaches to address critical gaps in pediatric rheumatology research by testing a novel and powerful resource for JIA research. The validation of this linkage between Registry and claims data will set a new standard in the field, providing a model that can readily be applied to other pediatric rheumatic diseases captured by the CARRA Registry, including systemic lupus erythematosus and juvenile dermatomyositis. The linked dataset will enable a wide variety of future investigations, including studies on risk factors, outcomes, healthcare utilization, comparative effectiveness, drug safety, biomarkers, adherence, deprescribing, mental health, and the transition from pediatric to adult rheumatology care, thereby improving JIA management and informing clinical and policy decisions. Through these aims, SPARCLe-JIA will enhance the utility of the CARRA Registry for future observational and interventional studies that will ultimately improve the management, monitoring, and outcomes of people with JIA and other pediatric rheumatic diseases.